Nicole Sweeny - Jun 18, 2025 Form 3 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: Chief Commercial Officer
Signature: /s/ Benjamin Palleiko, Attorney-in-Fact
Stock symbol: KALV
Transactions as of: Jun 18, 2025
Transactions value $: $0
Form type: 3
Date filed: 8/25/2025, 09:33 PM
Previous filing: Feb 13, 2023
Next filing: Aug 25, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sweeny Nicole	Chief Commercial Officer	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE	/s/ Benjamin Palleiko, Attorney-in-Fact	2025-08-25	0001827505

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KALV	Restricted Stock Unit							Jun 18, 2025	Common Stock	100K	$0.00	Direct	F1, F2
holding	KALV	Restricted Stock Unit							Jun 18, 2025	Common Stock	80K	$0.00	Direct	F2, F3
holding	KALV	Employee Stock Option							Jun 18, 2025	Common Stock	100K	$9.51	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/16th of the total number of shares subject to the Restricted Stock Unit ("RSU") shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.
F2	Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F3	1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date.
F4	The option vests over a 4 year period: 25% on June 24, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.